fiercebiotech.com
Agomab's ALK5 inhibitor hits intestinal target in Crohn's trial - Fierce Biotech
This report describes an investigational drug that appears to reach its intestinal target and produced molecular changes in biopsies from people with fibrostenosing Crohn’s — a form that causes scarring and strictures.
If later results show clinical benefit, it could become a treatment option aimed at fibrosis rather than just inflammation.
People with fibrostenosing Crohn’s, clinicians treating Crohn’s, researchers in IBD drug development, and patients interested in emerging anti-fibrotic therapies.
What To Know
Agomab reported interim phase 2 (STENOVA) results for AGMB-129, an ALK5-targeting small-molecule inhibitor being tested in fibrostenosing Crohn’s disease.
The interim readout in 90 patients showed the drug was safe and well tolerated over 12 weeks versus placebo, and the study met secondary endpoints including changes in mRNA gene expression in ileal biopsies and pharmacokinetic/metabolite measures.
Full data will be held for presentation at a future scientific conference and a complete readout is expected later in the year. The article focuses on target engagement (mRNA changes in ileal biopsies) and PK/metabolite findings rather than clinical efficacy outcomes.
It notes the drug is being developed to try to reduce scarring/fibrosis in fibrostenotic Crohn’s and may be considered for combination use with existing Crohn’s therapies. The company funded the program with a prior $100M Series C and acquired related TGF-beta–targeting candidates via an acquisition.
This is an interim, company-reported update; the company plans to release full results at a conference. There is no detailed efficacy or safety dataset in the article, and no clinical guidance for patients.
These are interim, company-announced phase 2 results focused on safety, target engagement (mRNA changes in ileal biopsies), and pharmacokinetics. The article does not present full efficacy or detailed safety data; full results are pending presentation at a scientific conference and later publication.
